Ambit Biosciences - Top 20 VC deals of 2007

Company: Ambit Biosciences
Based: San Diego-CA
Amount: $49M
Round: Forth
Investors: Aisling Capital, Avalon Ventures, Canadian Medical Discoveries Fund, F. Hoffmann - La Roche, Forward Ventures, GIMV, GeneChem Financial Corporation, MedImmune, OrbiMed Advisors, Radius Ventures, Undisclosed Investor, Undisclosed Venture Firm

Scoop: The funding is being used to support advancement of Ambit’s product pipeline, which includes several drug candidates in clinical and pre-clinical development. They included AC220 for Acute Myeloid Leukemia, a preclinical drug for colon, prostate, breast, lung, pancreatic and other cancers, and another drug for melanoma. Ambit was recently spotlighted in our weekly Emerging Drug Developer column. It was also a 2006 Fierce 15 company.

More News:
Emerging Drug Developer: Ambit Biosciences. Report
Ambit Biosciences garners $49M in Series D. Report

Ambit Biosciences - Top 20 VC deals of 2007

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.